Valore202020212022202320242025TTMSpese di vendita, generali e amministrative525.36 M584.47 M603.95 M579.17 M564.36 M583.67 M—Ricerca e sviluppo149.07 M189.96 M189.86 M198.51 M193.49 M187.52 M—Reddito operativo386.43 M630.08 M531.46 M409.94 M97.71 M465.85 M-397.68 MProventi non operativi, Totale53.04 M-4.25 M-18.86 M19.87 M23.44 M24.41 M—Oneri finanziari, al netto degli interessi capitalizzati71.32 M54.48 M58.36 M53.41 M86.44 M66.86 M—Proventi non operativi, esclusi gli oneri finanziari-132.6 M-99.4 M-83.96 M-27.83 M-62.27 M-35.79 M—Entrate/uscite straordinarie114.33 M40.67 M6.74 M-5.71 M-739 K-6.65 M—Utile al lordo delle imposte439.47 M625.83 M512.6 M429.81 M121.15 M490.26 M1.55 BQuota di utile5.02 M11.99 M3.76 M4.16 M5.72 M4.4 M—Imposte80.28 M113.23 M89.39 M88.51 M37.56 M65.39 M152.24 MInteressi di minoranza———————Altri proventi/oneri al netto delle imposte-11.7 M-5.62 M-22.73 M-7.62 M-8.39 M-13.11 M—Utile netto al lordo delle attività cessate359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BAttività cessate———————Utile netto359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BUtile base per azione (EPS base)1.662.391.971.540.381.96—Utile diluito per azione (EPS diluito)1.622.341.951.520.371.946.36Numero medio di azioni ordinarie in circolazione215.42 M215 M214.62 M221.81 M222.62 M217.22 M876.26 MAzioni diluite in circolazione220.88 M218.82 M217.03 M224.21 M224.72 M218.88 M884.84 MEBITDA527.95 M792.16 M679.18 M562.87 M258.38 M626 M—EBIT322.93 M577.23 M470.79 M357.53 M55.12 M432.25 M—Costo del fatturato637.63 M802.99 M762.53 M731.63 M1.01 B790.5 M—Altri costi del venduto574.47 M733.72 M696.47 M667.42 M952.32 M735.27 M—Ammortamento e svalutazione (liquidità)205.01 M214.93 M208.4 M205.34 M203.27 M193.75 M342.68 M
Qiagen N.V
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer.